SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

AimedBio and Boehringer Ingelheim Start Phase I Study of BI 4060107

AimedBio and Boehringer Ingelheim initiated a Phase I study of antibody-drug conjugate BI 4060107.

Related stories